Biocon share jumps 6% on USFDA's 'VAI' tag to Bengaluru facility; details

Q: How long will it take to read this news story?

The story "Biocon share jumps 6% on USFDA&#039;s &#039;VAI&#039; tag to Bengaluru facility; details" has 431 words across 21 sentences, which will take approximately 2 - 4 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Biocon share jumps 6% on USFDA&#039;s &#039;VAI&#039; tag to Bengaluru facility; details" was covered 6 days ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 157 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #23508897</li><li>URL: https://beamstart.com/news/biocon-share-jumps-6-on-17313033961555</li></ul>

Business Standard Logo Business Standard 6d ago

Biocon share jumps 6% on USFDA's 'VAI' tag to Bengaluru facility; details - Business Standard

Quick Summary:

At 10:44 AM, Biocon shares were trading 5.62 per cent higher at Rs 339.30 per share.

Biocon has made strides in novel biologics, with the introduction of India’s first indigenously produced monoclonal antibody, Nimotuzumab, and Itolizumab for treating psoriasis.

Syngene, its research services arm, is an independent entity that offers comprehensive discovery, development, and manufacturing services to various industries, including pharmaceuticals, biotechnology, and consumer goods.